Study In Components Compatibility Of Lyophilized Combined Hepatitis A And B Vaccine

Hepatitis A and B infectious diseases are a serious threat to people's health. How to effectively both treatment and prevention of the spread of HIV has been the focus of people's attention. especially in the developing countries including China, A, hepatitis B prevention task more arduous. Currently, the best way to control these two diseases is vaccinated.Preschool children in need of a vaccine against the total number up to 30 times. more than 80% of intramuscular vaccination, as a result, immune complex procedures, increase the chance of cross-infection. financial burdens that end, the World Health Organization (WHO) to promote to development combined vaccine vaccines. 1990s in the 20th century, and there are inactivated hepatitis A vaccine of hepatitis B vaccine and recombinant (yeast) vaccine combined vaccine made of The report, China has now a combined vaccine listing the species, and they are more expensive. And the live attenuated hepatitis A vaccine and recombinant hepatitis B vaccine (CHO cells) developed by our own scientists have independent intellectual property vaccine. On the basis of a combined hepatitis A and B vaccine developed by freeze-drying has not been previously reported. The combined vaccine because of its good security and stability especially notable is its low cost and better immune effect, it is more suitable for China's national conditions.This paper conducted in the following areas :[1] Appropri completed the combined vaccine component ratio, to determine a joint vaccine preparation.[2] Completed a screening agent for the stability of the combined vaccine.[3] On the combined vaccine with the corresponding price and more effective vaccine for the virus titer and the monkey immune effects. show that the combined vaccine with the monovalent vaccine is equally good safety and immunogenicity.In summary, the combined vaccine has broad market prospects, in order to prevent it becoming A-ideal hepatitis B vaccine We also need a lot of other work, including joint vaccine adjuvants screening, the stability of vaccine research. thus provide a sufficiently reliable basis for further applications.